Pluripotent cell–specific inhibitors (PluriSIns) to reduce the tumorigenic risk of stem cell–based therapies View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2013-02

ABSTRACT

PluriSIns that are selectively toxic to human pluripotent stem cells could reduce the tumorigenic risk of stem cell–based therapies. Residual undifferentiated stem cells in stem cell–derived cell therapies can lead to teratoma formation. A screen of about 50,000 small molecules identified 15 PluriSIns that were cytotoxic to human embryonic stem cells (ESCs) and induced pluripotent stem (iPS) cells but not to differentiated cells derived from these stem cells. In a mixture of differentiated and undifferentiated stem cells injected into mice, none of the cell mixtures pretreated with the lead PluriSIn developed teratomas, whereas all vehicle-treated cell mixtures did. Next steps include examining the ability of PluriSIns to reduce the risk of teratoma formation in vivo. More... »

PAGES

126-126

Journal

TITLE

Science-Business eXchange

ISSUE

5

VOLUME

6

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/scibx.2013.126

DOI

http://dx.doi.org/10.1038/scibx.2013.126

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1050686314


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1004", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical Biotechnology", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/10", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Technology", 
        "type": "DefinedTerm"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/j.stem.2012.11.015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019413404"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-02", 
    "datePublishedReg": "2013-02-01", 
    "description": "PluriSIns that are selectively toxic to human pluripotent stem cells could reduce the tumorigenic risk of stem cell\u2013based therapies. Residual undifferentiated stem cells in stem cell\u2013derived cell therapies can lead to teratoma formation. A screen of about 50,000 small molecules identified 15 PluriSIns that were cytotoxic to human embryonic stem cells (ESCs) and induced pluripotent stem (iPS) cells but not to differentiated cells derived from these stem cells. In a mixture of differentiated and undifferentiated stem cells injected into mice, none of the cell mixtures pretreated with the lead PluriSIn developed teratomas, whereas all vehicle-treated cell mixtures did. Next steps include examining the ability of PluriSIns to reduce the risk of teratoma formation in vivo.", 
    "genre": "non_research_article", 
    "id": "sg:pub.10.1038/scibx.2013.126", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1136657", 
        "issn": [
          "1945-3477"
        ], 
        "name": "Science-Business eXchange", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "6"
      }
    ], 
    "name": "Pluripotent cell\u2013specific inhibitors (PluriSIns) to reduce the tumorigenic risk of stem cell\u2013based therapies", 
    "pagination": "126-126", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "f1739241d1a2c12d5fcae41c16e32e9ac2b250e172b13718e4e0aa8466343237"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/scibx.2013.126"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1050686314"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/scibx.2013.126", 
      "https://app.dimensions.ai/details/publication/pub.1050686314"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T23:12", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8693_00000426.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://www.nature.com/scibx/journal/v6/n5/full/scibx.2013.126.html"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/scibx.2013.126'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/scibx.2013.126'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/scibx.2013.126'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/scibx.2013.126'


 

This table displays all metadata directly associated to this object as RDF triples.

52 TRIPLES      20 PREDICATES      27 URIs      18 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/scibx.2013.126 schema:about anzsrc-for:10
2 anzsrc-for:1004
3 schema:citation https://doi.org/10.1016/j.stem.2012.11.015
4 schema:datePublished 2013-02
5 schema:datePublishedReg 2013-02-01
6 schema:description PluriSIns that are selectively toxic to human pluripotent stem cells could reduce the tumorigenic risk of stem cell–based therapies. Residual undifferentiated stem cells in stem cell–derived cell therapies can lead to teratoma formation. A screen of about 50,000 small molecules identified 15 PluriSIns that were cytotoxic to human embryonic stem cells (ESCs) and induced pluripotent stem (iPS) cells but not to differentiated cells derived from these stem cells. In a mixture of differentiated and undifferentiated stem cells injected into mice, none of the cell mixtures pretreated with the lead PluriSIn developed teratomas, whereas all vehicle-treated cell mixtures did. Next steps include examining the ability of PluriSIns to reduce the risk of teratoma formation in vivo.
7 schema:genre non_research_article
8 schema:inLanguage en
9 schema:isAccessibleForFree true
10 schema:isPartOf N316edc0dc25849cea1dc9dcfb5b2275a
11 Na1978211a16a455bbfd2dbe76bb2cb3b
12 sg:journal.1136657
13 schema:name Pluripotent cell–specific inhibitors (PluriSIns) to reduce the tumorigenic risk of stem cell–based therapies
14 schema:pagination 126-126
15 schema:productId N04965485b0574090ac4293df34868cfd
16 N16bae3d6c0374b0abd5d0485a8832f44
17 N38f4c26925d74e638203084ed535d44d
18 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050686314
19 https://doi.org/10.1038/scibx.2013.126
20 schema:sdDatePublished 2019-04-10T23:12
21 schema:sdLicense https://scigraph.springernature.com/explorer/license/
22 schema:sdPublisher N0ae9a8ff6500440f9be791f90ae3f4fa
23 schema:url http://www.nature.com/scibx/journal/v6/n5/full/scibx.2013.126.html
24 sgo:license sg:explorer/license/
25 sgo:sdDataset articles
26 rdf:type schema:ScholarlyArticle
27 N04965485b0574090ac4293df34868cfd schema:name readcube_id
28 schema:value f1739241d1a2c12d5fcae41c16e32e9ac2b250e172b13718e4e0aa8466343237
29 rdf:type schema:PropertyValue
30 N0ae9a8ff6500440f9be791f90ae3f4fa schema:name Springer Nature - SN SciGraph project
31 rdf:type schema:Organization
32 N16bae3d6c0374b0abd5d0485a8832f44 schema:name dimensions_id
33 schema:value pub.1050686314
34 rdf:type schema:PropertyValue
35 N316edc0dc25849cea1dc9dcfb5b2275a schema:issueNumber 5
36 rdf:type schema:PublicationIssue
37 N38f4c26925d74e638203084ed535d44d schema:name doi
38 schema:value 10.1038/scibx.2013.126
39 rdf:type schema:PropertyValue
40 Na1978211a16a455bbfd2dbe76bb2cb3b schema:volumeNumber 6
41 rdf:type schema:PublicationVolume
42 anzsrc-for:10 schema:inDefinedTermSet anzsrc-for:
43 schema:name Technology
44 rdf:type schema:DefinedTerm
45 anzsrc-for:1004 schema:inDefinedTermSet anzsrc-for:
46 schema:name Medical Biotechnology
47 rdf:type schema:DefinedTerm
48 sg:journal.1136657 schema:issn 1945-3477
49 schema:name Science-Business eXchange
50 rdf:type schema:Periodical
51 https://doi.org/10.1016/j.stem.2012.11.015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019413404
52 rdf:type schema:CreativeWork
 




Preview window. Press ESC to close (or click here)


...